About Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7
Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 (JMJD7) is a protein
from Homo sapiens identified by UniProt accession
P0C870, 316 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 |
|---|
| UniProt accession | P0C870 |
|---|
| Gene | JMJD7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 316 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (45)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.23
- neurodegenerative disease · score 0.23
- BMI-adjusted waist-hip ratio · score 0.15
- diastolic blood pressure · score 0.14
- FEV/FVC ratio · score 0.14
- systolic blood pressure · score 0.14
- lean body mass · score 0.13
- diabetes mellitus · score 0.12
- waist-hip ratio · score 0.12
- body mass index · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0C870-F1 | alphafold | PREDICTED | 97.85 | — |
Amino-acid sequence (316 residues)
MAEAALEAVR SELREFPAAA RELCVPLAVP YLDKPPTPLH FYRDWVCPNR PCIIRNALQH WPALQKWSLP YFRATVGSTE VSVAVTPDGY ADAVRGDRFM MPAERRLPLS FVLDVLEGRA QHPGVLYVQK QCSNLPSELP QLLPDLESHV PWASEALGKM PDAVNFWLGE AAAVTSLHKD HYENLYCVVS GEKHFLFHPP SDRPFIPYEL YTPATYQLTE EGTFKVVDEE AMEKVPWIPL DPLAPDLARY PSYSQAQALR CTVRAGEMLY LPALWFHHVQ QSQGCIAVNF WYDMEYDLKY SYFQLLDSLT KASGLD
Explore Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets